Clinically, NGAL may be a marker of CKD progression as well (Mitsnefes et al., 2007; Bolignano et al., 2008, 2009; Malyszko et al., 2008; Carrero and Stenvinkel, 2011; Bhavsar et al., 2012; AvciÇiçek et al., 2016). This evidence concerns the gene LCN2 and chronic kidney disease.